In preclinical versions.

In this trial, participants will receive either placebo or a minimal dosage of GGF2 administered as a single intravenous infusion. If GGF2 is normally well tolerated, subsequent groups shall receive one infusions of higher doses. GGF2, which is part of a grouped family of proteins known as neuregulins, has been shown to be pharmacologically active in several preclinical types of cardiovascular and neurological circumstances. GGF2 acts on heart muscle cells directly, or cardiomyocytes.From 22-26 August, 2010. The primary theme of this meeting is certainly Chemistry for Combating and Preventing Disease, and the presentations are being made at the Oligonucleotide Therapeutics Symposium organized by the Carbohydrate Division of ACS. Data being presented by Alnylam researchers as of this meeting include fresh results on style, synthesis, and characterization of siRNAs, siRNA conjugates, and delivery formulations. Certainly, these cumulative data demonstrate Alnylam’s continued scientific leadership in the advancement of RNAi therapeutics as a new class of innovative medicines, stated Muthiah Manoharan, Ph.D., Senior Vice President, Drug Discovery.